Whether you are a new T1D Family, a TrialNet participant, a healthcare provider, or a researcher — you'll find resources here.
We’re here to help you after a new T1D diagnosis. Get answers to frequently asked questions and learn about clinical studies testing ways to maintain insulin production.
While you wait for screening results, get answers to your questions, find out about next steps, and learn more about TrialNet’s Pathway to Prevention.
Your T1D families are important to you. Learn how easy it is to connect your patients with world-class T1D research.
University of Missouri
CRC-N508 Health Science #1, Hospital Dr, Columbia, MO 65212
Truman Medical Center
2411 Holmes St, SOM M4-329, Kansas City, MO 64108
KU Diabetes Institute - University of Kansas Medical Center
3901 Rainbow Blvd. MS 1064, Kansas City, KS 33160
University of Nebraska Medical Center
985456 Nebraska Medical Center, Omaha, NE 68198
Cotton-O'Neil Clinical Research Center
3520 SW 6th Avenue, Topeka, KS 66606
If you have a relative with T1D, you’re in a unique position to help us learn more about the disease and how to stop it. The first step is to sign up for Pathway to Prevention screening to determine your risk of developing T1D.
TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 to stage 2) and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression.
We are testing the drug teplizumab to see if it can delay or prevent progression of early stage T1D (stage 2) and prevent clinical diagnosis (stage 3). In earlier studies in people newly diagnosed (stage 3), teplizumab helped to prolong insulin production.
Once your study ends, we're still here for you. Participant monitoring and continued involvement helps us learn more about T1D.